Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$80,129.00+0.25%ETH$2,324.65+0.23%GOLD$4,027.20-0.28%OIL$101.22-0.53%
Smart Investors Daily
SID Premium
KY

NASDAQ · KYTX

Kyverna Therapeutics, Inc.

Healthcare · Biotechnology

$5.27

Down-$0.12 (-2.23%)

Updated Oct 27, 2026, 6:21 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
364.57M
P/E ratio
-2.27
Dividend yield
0.00%
52-week range
$5.36 – $11.62
Volume
810.11K
Avg. volume
697.76K

Price performance · KYTX

KYTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

KYTX closed at $5.27 after 21 trading sessions, down 22.73% for the selected period.

Last close
$5.27
Period change
-22.73%
Period low
$5.27
Period high
$6.84
Daily close
View OHLC price history
KYTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$5.35$5.41$5.18$5.27810.11K
Oct 23, 2026$5.68$5.68$5.36$5.39827.75K
Oct 22, 2026$5.825$5.985$5.67$5.73519.39K
Oct 21, 2026$6.15$6.30$5.80$5.84829.52K
Oct 20, 2026$5.83$6.20$5.80$6.04766.31K
Oct 19, 2026$5.71$5.94$5.67$5.83837.71K
Oct 16, 2026$5.94$6.05$5.64$5.67726.28K
Oct 15, 2026$5.67$6.02$5.67$5.97779.43K
Oct 14, 2026$5.76$5.845$5.61$5.6851.28M
Oct 13, 2026$6.17$6.17$5.755$5.771.25M
Oct 12, 2026$6.34$6.46$6.19$6.21417.11K
Oct 9, 2026$6.20$6.58$6.175$6.39876.45K
Oct 8, 2026$6.06$6.2162$5.9602$6.181.32M
Oct 7, 2026$6.12$6.31$6.02$6.17650.55K
Oct 6, 2026$6.38$6.45$6.13$6.16739.52K
Oct 5, 2026$6.30$6.435$6.00$6.32813.48K
Oct 2, 2026$6.62$6.7537$6.17$6.221.18M
Oct 1, 2026$6.80$6.91$6.51$6.52788.5K
Sep 30, 2026$6.875$7.10$6.73$6.80746.99K
Sep 29, 2026$6.83$6.95$6.75$6.84827.67K
Sep 28, 2026$6.72$6.95$6.65$6.82997.82K

Latest KYTX news

The latest Smart Investors Daily articles mentioning KYTX.

Stock researchCompany · Overview

KYTX research

Overview

Company profile and research snapshot.

Company profile

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.50
Implied upside
—
Analysts
—
KYTX recent ratings
DateFirmRatingTarget
Jun 3, 2026HC Wainwright & Co.Buy—
May 15, 2026HC Wainwright & Co.Buy—
May 13, 2026JP MorganOverweight—
Apr 23, 2026HC Wainwright & Co.Buy—
Dec 16, 2025Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto

Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies Deep B-cell depletion demonstrated with a single dose supports the potential for broad immune reset enabled by miv-cel's unique construct Consistent, well-tolerated safety profile with no high-grade CRS or ICANS, and no cases of IEC-HS in one-year follow-up Data further strengthens SPS BLA package and supports potent

Yahoo · Oct 7, 2026

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS Updated Phase 1 investigator-initiated trial data to be presented, continuing to highlight encouraging clinical activity and a well-tolerated safety profile in progressive multiple sclerosis EMERYVILLE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, I

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By